-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IM-19 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IM-19 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IM-19 in B-Cell Acute Lymphocytic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IM-19 in B-Cell Chronic Lymphocytic Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IM-19 in B-Cell Chronic Lymphocytic Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IM-19 in B-Cell Chronic Lymphocytic Leukemia Drug Details: IM-19...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Tazemetostat Hydrobromide in Malignant Mesothelioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tazemetostat Hydrobromide in Malignant Mesothelioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tazemetostat Hydrobromide in Malignant Mesothelioma Drug Details: Tazemetostat hydrobromide (Tazverik) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SENL-B19 in Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SENL-B19 in Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SENL-B19 in Non-Hodgkin Lymphoma Drug Details: SENL-B19 (SENL-001) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SENL-B19 in Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SENL-B19 in Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SENL-B19 in Leukemia Drug Details: SENL-B19 (SENL-001) is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ibrutinib in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ibrutinib in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ibrutinib in Follicular Lymphoma Drug Details: Ibrutinib (Imbruvica) is an anti-neoplastic agent....
-
Company Insights
Aviva – Digital Transformation Strategies
Aviva Digital Transformation Strategies Overview Aviva is strengthening its focus on the use of innovative technologies to enhance its digital capabilities. AI, big data, insurtech, regtech, and cyber insurance are among the technologies the company is concentrating on. The annual ICT spending of Aviva is estimated at $506.5 million for 2023. A major share of this spending is earmarked for acquiring software, ICT services, and network and communications from vendors. Aviva is a multinational insurance and financial services group offering...
-
Product Insights
Injectable Drug Delivery Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Injectable Drug Delivery Pipeline Market Report Overview Injectable drug delivery devices help administer a drug into a patient’s blood. The Injectable Drug Delivery pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key Segments ·       Sustained Release Injectable...
-
Product Insights
Parasitology and Mycology Rapid Tests and POC Pipeline by Development Stages, Segments, Countries, Regulatory Path and Key Companies
Parasitology and Mycology Rapid Tests and POC Pipeline Market Report Overview Parasitology and mycology consist of rapid test kits. These are used for rapid diagnosis, with immediate results, through immunoassays for Plasmodium and Candida albicans. The Parasitology and Mycology Rapid Tests and POC pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress,...